Macrogenics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-24.1%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
$0.04next fiscal year
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly2K
MGC026 Phase 1 Initial Clinical Data AnnuallyTarget: Mid-2026
MGC028 Phase 1 Initial Clinical Data AnnuallyTarget: Second Half of 2026
MGC030 IND Submission AnnuallyTarget: Third Quarter of 2026
Watch Items
- LINNET Phase 2 Study of LorigerlimabTrigger: Safety events or clinical holdsAction: Monitor FDA feedback and protocol-defined safety measures following the removal of the partial clinical hold in April 2026.
- Bora Pharmaceuticals GMP Manufacturing DivestitureTrigger: Transaction closing in Q3 2026Action: Verify receipt of $122.5 million upfront proceeds and transition to a fully outsourced manufacturing model.
- MGC026 (B7-H3 ADC) Safety ProfileTrigger: Occurrence of Interstitial Lung Disease (ILD) or severe toxicitiesAction: Evaluate upcoming Phase 1 clinical data in mid-2026 to confirm safety differentiation from discontinued vobra duo.
Research as of 19 Jun 2026